246 related articles for article (PubMed ID: 19050386)
1. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Huang J; Meixner L; Fernandez S; McCutchan JA
AIDS; 2009 Jan; 23(1):51-7. PubMed ID: 19050386
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
3. The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.
Bourke S; Bolland MJ; Grey A; Horne AM; Wattie DJ; Wong S; Gamble GD; Reid IR
Osteoporos Int; 2013 Jan; 24(1):349-54. PubMed ID: 22893357
[TBL] [Abstract][Full Text] [Related]
4. Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Reid IR; Horne AM; Mihov B; Stewart A; Garratt E; Wong S; Wiessing KR; Bolland MJ; Bastin S; Gamble GD
N Engl J Med; 2018 Dec; 379(25):2407-2416. PubMed ID: 30575489
[TBL] [Abstract][Full Text] [Related]
5. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2007 Apr; 92(4):1283-8. PubMed ID: 17227801
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
7. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Negredo E; Bonjoch A; Pérez-Álvarez N; Ornelas A; Puig J; Herrero C; Estany C; del Río L; di Gregorio S; Echeverría P; Clotet B
HIV Med; 2015 Aug; 16(7):441-8. PubMed ID: 25944411
[TBL] [Abstract][Full Text] [Related]
9. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
Pinzone MR; Moreno S; Cacopardo B; Nunnari G
AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
[TBL] [Abstract][Full Text] [Related]
10. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.
Patel DV; Bolland M; Nisa Z; Al-Abuwsi F; Singh M; Horne A; Reid IR; McGhee CN
Osteoporos Int; 2015 Feb; 26(2):499-503. PubMed ID: 25187119
[TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
J Clin Endocrinol Metab; 2012 Jun; 97(6):1922-8. PubMed ID: 22419728
[TBL] [Abstract][Full Text] [Related]
12. Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.
Grey A; Bolland MJ; Horne A; Wattie D; House M; Gamble G; Reid IR
Bone; 2012 Jun; 50(6):1389-93. PubMed ID: 22465268
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Shane E; Cohen A; Stein EM; McMahon DJ; Zhang C; Young P; Pandit K; Staron RB; Verna EC; Brown R; Restaino S; Mancini D
J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
[TBL] [Abstract][Full Text] [Related]
14. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
[TBL] [Abstract][Full Text] [Related]
15. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
[TBL] [Abstract][Full Text] [Related]
18. Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial.
Grey A; Bolland M; Wong S; Horne A; Gamble G; Reid IR
J Clin Endocrinol Metab; 2012 Jan; 97(1):286-92. PubMed ID: 22072741
[TBL] [Abstract][Full Text] [Related]
19. Duration of antiresorptive activity of zoledronate in postmenopausal women with osteopenia: a randomized, controlled multidose trial.
Grey A; Bolland MJ; Horne A; Mihov B; Gamble G; Reid IR
CMAJ; 2017 Sep; 189(36):E1130-E1136. PubMed ID: 28893875
[TBL] [Abstract][Full Text] [Related]
20. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
